PCN68 COST-EFFECTIVENESS OF CETUXIMAB (ERBITUXTM) FOR THE FIRST LINE TREATMENT OF SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN CANADA

Value in Health ◽

10.1016/s1098-3015(10)73305-2 ◽

2009 ◽

Vol 12 (3) ◽

pp. A49 ◽

Author(s):

JC Sambrook ◽

AR Levy ◽

KM Johnston ◽

NJ Ricard ◽

C Bourgault ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Line Treatment ◽

First Line Treatment

Download Full-text

Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina

Advances in Therapy ◽

10.1007/s12325-021-01656-3 ◽

2021 ◽

Author(s):

Victoria Wurcel ◽

Diana Chirovsky ◽

Rebekah Borse ◽

Juan Ignacio Altuna ◽

Fernando Carabajal ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Line Treatment ◽

First Line Treatment

Download Full-text

271P Cost-effectiveness of pembrolizumab as monotherapy or in combination with chemotherapy versus EXTREME regimen for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in Taiwan

Annals of Oncology ◽

10.1016/j.annonc.2020.10.265 ◽

2020 ◽

Vol 31 ◽

pp. S1349

Author(s):

C.H. Wang ◽

H.L. Lei ◽

R. Borse ◽

D. Chirovsky ◽

L. Chien ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Line Treatment ◽

First Line Treatment

Download Full-text

FDA approves pembrolizumab for first-line treatment of head and neck squamous cell carcinoma

Case Medical Research ◽

10.31525/cmr-14e3317 ◽

2019 ◽

Author(s):

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Line Treatment ◽

First Line Treatment

Download Full-text

Cetuximab, Docetaxel and Cisplatin as First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results of the GORTEC 2014-01 TPExtreme Randomized Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3700967 ◽

2020 ◽

Author(s):

Joël Guigay ◽

Anne Aupérin ◽

Jerome Fayette ◽

Esma Saada-Bouzid ◽

Cédrik Lafond ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Randomized Trial ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Line Treatment ◽

First Line Treatment

Download Full-text

Observational study of the cetuximab relative dose intensity (RDI) in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Data on the maintenance and every two weeks use (DIRECT study)

Annals of Oncology ◽

10.1093/annonc/mdw376.19 ◽

2016 ◽

Vol 27 ◽

pp. vi334 ◽

Author(s):

J. Guigay ◽

E. Chamorey ◽

P. Céruse ◽

F. Mornex ◽

M. Degardin ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Observational Study ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Dose Intensity ◽

Line Treatment ◽

Metastatic Squamous Cell Carcinoma ◽

First Line Treatment

Download Full-text

972TiP Phase II study of intratumoral MK-1454 plus pembrolizumab compared with pembrolizumab monotherapy as first-line treatment for metastatic or unresectable, recurrent head and neck squamous cell carcinoma

Annals of Oncology ◽

10.1016/j.annonc.2020.08.1087 ◽

2020 ◽

Vol 31 ◽

pp. S683

Author(s):

K.J. Harrington ◽

W.N. William ◽

A. Khilnani ◽

A.P. Algazi

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Line Treatment ◽

Recurrent Head ◽

First Line Treatment

Download Full-text

Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma

Cancer ◽

10.1002/cncr.30067 ◽

2016 ◽

Vol 122 (15) ◽

pp. 2350-2355 ◽

Author(s):

Jared M. Weiss ◽

Stephen Bagley ◽

Wei-Ting Hwang ◽

Joshua Bauml ◽

Juneko Grilley Olson ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Line Treatment ◽

Recurrent Head ◽

First Line Treatment

Download Full-text

Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048

Annals of Oncology ◽

10.1093/annonc/mdv514.01 ◽

2015 ◽

Vol 26 ◽

pp. viii5 ◽

Author(s):

A. Klochikhin ◽

R. Greil ◽

E. Cohen ◽

J. Vermorken ◽

K. Harrington ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Line Treatment ◽

Phase 3 ◽

First Line Treatment

Download Full-text

123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial

Annals of Oncology ◽

10.1016/j.annonc.2021.10.142 ◽

2021 ◽

Vol 32 ◽

pp. S1432

Author(s):

D.A. Colevas ◽

K. Misiukiewicz ◽

A.T. Pearson ◽

J. Fayette ◽

J.R. Bauman ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Line Treatment ◽

Metastatic Squamous Cell Carcinoma ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13355993.791652823 ◽

2012 ◽

Author(s):

Marco Merlano

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Line Treatment ◽

Metastatic Squamous Cell Carcinoma ◽

First Line Treatment

Download Full-text